Medpace Holdings, Inc.

NasdaqGS:MEDP

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

Location

United States

Market Cap

USD 8.93 B

Share Price

USD 310.69

Avg Daily Volume

494,823

Change (1 day)

1.27%

Change (1 year)

-26.78%

Change (YTD)

-6.48%

Medpace Holdings, Inc. Revenue Year-on-Year (YoY) growth for the Trailing 12 Months (TTM) ending March 31, 2025: 9.87%

Medpace Holdings, Inc. Revenue Year-on-Year (YoY) growth is 9.87% for the Trailing 12 Months (TTM) ending March 31, 2025. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period. Year-on-Year (YoY) growth is the change in a financial metric compared to the same period in the previous year, expressed as a percentage.

Medpace Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 1.96 B, a 25.57% change year over year.
Medpace Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 1.56 B, a 28.83% change year over year.
Medpace Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 1.21 B, a 27.05% change year over year.
Medpace Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 955.01 M, a 7.17% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Year-on-Year (YoY) growth	Gross Profit	Operating Income	EBIT

NasdaqGS: MEDP

Medpace Holdings, Inc.

CEO	Dr. August James Troendle M.D.
IPO Date	Aug. 11, 2016
Location	United States
Headquarters	5375 Medpace Way
Employees	5,900
Sector	🏥 Health Care
Industries Clinical Trials

Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.